# Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

> **NCT05768321** · PHASE1 · UNKNOWN · sponsor: **GenEros Biopharma Hangzhou Ltd** · enrollment: 70 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** GEC255 tablets

## Key facts

- **NCT ID:** NCT05768321
- **Lead sponsor:** GenEros Biopharma Hangzhou Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-04
- **Primary completion:** 2024-02-28
- **Final completion:** 2024-05-30
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2023-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05768321

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05768321, "Study of GEC255 in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05768321. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*